1. Elevated plasma Galectin-3 is associated with major adverse kidney events and death after ICU admission
- Author
-
Boutin, L, Legrand, M, Sadoune, M, Mebazaa, A, Gayat, E, Chadjichristos, CE, and Dépret, F
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Clinical Research ,Kidney Disease ,Prevention ,Renal and urogenital ,Good Health and Well Being ,Acute Kidney Injury ,Biomarkers ,Critical Illness ,Female ,Galectin 3 ,Humans ,Intensive Care Units ,Kidney ,Middle Aged ,Prospective Studies ,Acute kidney injury ,Galectin-3 ,Major Adverse Kidney Event ,Renal biomarker ,Medical and Health Sciences ,Emergency & Critical Care Medicine ,Biomedical and clinical sciences ,Health sciences - Abstract
BackgroundGalectin-3 (Gal-3) is a proinflammatory and profibrotic protein especially overexpressed after Acute Kidney Injury (AKI). The early renal prognostic value of Gal-3 after AKI in critically ill patients remains unexplored. The objective was to evaluate the prognostic value of plasma level of Gal-3 for Major Adverse Kidney Events (MAKE) and mortality 30 days after ICU admission across AKI stages.MethodsThis is an ancillary study of a prospective, observational, multicenter cohort (FROG-ICU). AKI was defined using KDIGO definition.ResultsTwo thousand and seventy-six patients had a Gal-3 plasma level measurement at ICU admission. Seven hundred and twenty-three (34.8%) were females and the median age was 63 [51, 74] years. Eight hundred and seven (38.9%) patients developed MAKE, 774 (37.3%) had AKI and mortality rate at 30 days was 22.4% (N = 465). Patients who developed MAKE had higher Gal-3 level at admission compared to patients without (30.2 [20.8, 49.2] ng/ml versus 16.9 [12.7, 24.3] ng/ml, p
- Published
- 2022